Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 8/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.45 |
| ▸ | HTR3B | O95264 | 3/20 | 0.45 |
| ▸ | HTR3A | P46098 | 3/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.45 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.43 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9980600 | 0.98 | ADRB1 (0.46) | ADRB1ADRB2NCF1PLD1HTR3E | |
| Trifluoroacetic Acid SCHEMBL26599776 | 0.84 | HRH4 (0.42) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Trifluoroacetic Acid SCHEMBL30282808 | 0.84 | HRH4 (0.42) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Tert-Butyl Formate SCHEMBL28316936 | 0.83 | ADRB1 (0.39) | ADRB1ADRB2NCF1PLD1HTR3E | |
| SCHEMBL18107430 | 0.81 | CHKA (0.41) | ACVR1 | |
| SCHEMBL18107285 | 0.79 | ROCK2 (0.41) | — | |
| SCHEMBL6883030 | 0.79 | ALDH1A1 (0.46) | HTR3AACVR1 | |
| SCHEMBL31580242 | 0.78 | CHRNB2 (0.39) | HTR3ACHRNB2CHRNA4 | |
| SCHEMBL18107278 | 0.76 | LMNA (0.45) | — | |
| SCHEMBL28488265 | 0.74 | BMPR1B (0.46) | CHRNB2CHRNA4BMPR1BBMPR1AACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4543450-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2025-03-11 | — | — | US | disclosed |
| CN-119546304-A | Salts of SOS1 inhibitors | 米拉蒂治疗公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119403806-A | TREM2 modulators | 穆纳治疗有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-110198938-A | Double-heteroaryl derivative as protein aggregation regulator | UCB生物制药私人有限公司 | 2019-09-03 | — | — | CN | disclosed |
| US-8883850-B2 | Naphthalene carboxamide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883850-B2 | Naphthalene carboxamide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130345215-A1 | PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-26 | — | — | US | disclosed |
| WO-2013066729-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130059860-A1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-03-07 | — | — | US | disclosed |
| US-20130059860-A1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-03-07 | — | — | US | disclosed |
| WO-2012158475-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2011149801-A1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011137049-A1 | HETEROCYCLIC QUINOLIZINE DERIVED M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | ADRB1 746/4885ADRB2 1055/4885NCF1 1586/4885 |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | ADRB1 2570/4885ADRB2 3395/4885NCF1 1564/4885 |
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | SOS1, SOS2, SOST | ADRB1 3378/4885ADRB2 4025/4885NCF1 1083/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | ADRB1 2912/4885ADRB2 3589/4885NCF1 736/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | ADRB1 2912/4885ADRB2 3589/4885NCF1 736/4885 |
| US-20130059860-A1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CNR1, OPRL1 | ADRB1 69/4885ADRB2 151/4885NCF1 560/4885 |
| US-20130345215-A1 | PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE | TNKS1BP1, TPI1, TNKS | ADRB1 4344/4885ADRB2 4642/4885NCF1 2627/4885 |
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | CBR1, CBR3, CNR1 | ADRB1 11/4885ADRB2 29/4885NCF1 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.